

Our ref: IG/FOI/FOI.019.26

21 January 2026

Sent via email to: [REDACTED]

Dear [REDACTED]

## Request under the Freedom of Information Act 2000

I write further to your request for information which was received on 13 January 2026, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does not hold the information that you require. For ease of reference your request is set out below and the Health Board's response follows.

### Your Freedom of Information (FOI) Request:

I am writing to request the following information under the Freedom of Information Act (FOIA).

Q1. How many patients with HIV in total were seen for care and treated with ART in your Trust in the latest 3 months of available data?

\_\_\_\_\_ total patients treated with ART

Q2. How many patients newly diagnosed with HIV were initiated on Antiretroviral Therapy (ART) in your Trust in the latest 3 months of available data?

\_\_\_\_\_ total patients newly diagnosed initiated on ART

Q3. How many patients with HIV have had their ART switched in your Trust in the latest 3 months of available data?

\_\_\_\_\_ patients who switched therapy

Q 4. Of the patients identified in Question 3, how many were switched from/ to the following therapies?

Therapy	Total switched patients
Emtricitabine/tenofovir alafenamide (fixed dose combination) + any other ART to Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)	

Emtricitabine/tenofovir alafenamide (fixed dose combination) + any other ART to Dovato (dolutegravir/lamivudine)	
Emtricitabine/tenofovir disoproxil (fixed dose combination) + any other ART to Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)	
Emtricitabine/tenofovir disoproxil (fixed dose combination) + any other ART to Dovato (dolutegravir/lamivudine)	
Triumeq (dolutegravir/abacavir/lamivudine) to Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)	
Triumeq (dolutegravir/abacavir/lamivudine) to Dovato (dolutegravir/lamivudine)	
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) to Dovato (dolutegravir/lamivudine)	
Any other ART** to Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)	
Any other ART** to Dovato (dolutegravir/lamivudine)	

\*\* NOTE: "Any other ART" - if the patient was given one of the regimens listed earlier, leave that patient in the rows above so they are not double counted.

Q5. Please specify the dates of the latest 3 months of available date in month / year format.

\_\_\_\_\_ MM/YY

**Powys Response:**

I can confirm that our response remains unchanged from your previous request FOI.615.25. Powys Teaching Health Board (PTHB) does not directly provide HIV treatment services. Patients requiring antiretroviral therapy are referred to specialist services delivered by providers outside Powys.

If you have queries or any concerns, contact details are given at the top of the letter. Please remember to quote the reference number above in any future communications. If you are dissatisfied with the handling or response to your request and wish to ask for a review of this, please contact us and we will arrange for this to be done.

Further information is available from the Information Commissioner's Office who can be contacted at:

Address: Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH.

Telephone: 0330 414 6421

Complaints Portal: [www.ico.org.uk/foicomplaints](http://www.ico.org.uk/foicomplaints)

Web site: <https://ico.org.uk/>


**Re-use of Public Sector Information**

All information supplied by the Health Board in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2015.

Under the terms of the Regulations, the Health Board will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however, the Health Board reserves the right, in certain circumstances to charge a fee for the re-use of some information which it deems to be of commercial value.

Further information including a sample license terms and fees can be found at [Open Government Licence](#).

Yours sincerely



**Amie Symes**  
**Director of Midwifery, Women and Family**

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.